TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature

TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature

Blog Article

Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma (ALK+ LBCL) is an aggressive and rare subtype chicago bears garden gnome of B-cell lymphoma.Patients typically present with advanced clinical stage disease and do not respond to conventional chemotherapy; the median overall survival is 1.8 years.

The genetic landscape of this entity remains poorly understood.Here we report a unique case of ALK+ LBCL harbouring a rare TFG::ALK fusion.Targeted next-generation sequencing showed no significant single nucleotide variants, insertions/deletions, or other structural variants beyond the TFG::ALK fusion; deep deletions of FOXO1, PRKCA, and the MYB locus were also detected.

Our case report draws attention to this rare disease, highlights a need for larger genetic profiling skin of the flayed one studies, and focuses on the pathogenesis and potential therapeutic targets of this aggressive disease.To our knowledge, this is the first report of a TFG::ALK fusion in ALK+ LBCL.